AFLB Now Confirmed as Potential Pfizer Buyout Target

A5 Labs (AFLB) Has Just Announced The Greatest Medical Discovery Of The 21st Century! Invest now while shares are just 73 cents and you could watch them explode to $35 or more! Just $5k may jump to $239,726 - even before a high priced buyout by Big Pharma. I'll prove below, why a buyout by Merck, Pfizer or Johnson & Johnson... may be virtually guaranteed! Friend, I'm about to reveal to you what could be the biggest medical breakthrough in the last 100 years - and exactly how it can make you a millionaire practically overnight... A5 Laboratories (AFLB), has just unveiled a way to produce one of the most critical ingredients needed in many of the world's biggest-selling drugs - it's called interferon - and it's setting AFLB up as a strong buyout target by a major pharmaceutical company, like Roche or Johnson & Johnson. I'm going to lay out for you exactly why a buyout of A5 Labs at $35 a share could be right around the corner. But before we get into the big buyout possiblities, let me tell you about their earthshattering new discovery... What are interferons - and why are they so important? Besides being the keys to unlocking your door to untold wealth... Interferons are critical immune proteins that fight disease and even human cancer cells. They're produced naturally by your body and help keep you healthy. Too few interferons and death could be knocking at your door. This is why they're used by many of today's largest pharmaceutical manufacturers in dozens of blockbuster drugs. Interferon is basically one of the major keys to these gigantic drug company's financial success. Without interferon, some Blockbuster drugs could be dead in the water. But unfortunately for Big Pharma, this keystone ingredient has been highly-toxic, rediculously expensive and sadly enough, gentically engineered... Until now. As we speak, A5 Labortories (AFLB) are creating an inexpensive, non-toxic and completely natural interferon that could turn the entire medical world on it's head, and by doing so, capturing 100% of the interferon market... Yes, you heard me right - 100%! But best of all, (especially for people like us) A5 Laboratories (AFLB) is planning on selling their damn-near perfect interferon to Big Pharma for just 1/7th the price they're paying now - which could potentially mean profit margins in excess of 93%! Why I see a fast and high-priced buyout of AFLB on the horizon Of course, the fastest way for AFLB to become a Billion dollar company is obvioulsy the big money buyout, which I'm about to prove to you, could be a virtual certainty. But there's another path A5 could take.. AFLB may very well cut a highly-lucrative licensing deal with Big Pharma names like Pfizer and Roche, to make and add A5's interferon to their already successful drugs. Assuming A5's interferon makes these drugs far more superior, sales could easily double, as it becomes the drug of choice. Then, A5 will collect a percentage-of-sales royalty on the new formulations. And if Pfizer and Roche don't want in, I'm sure Biogen would love to add A5's interferon to its products, maybe quadrupling its current $1.7 billion annual sales to $6.8 Billion, while largely killing sales of those companies sitting on the sidelines. Now Pfizer could stop all of this monkey business and buy AFLB straight out at a potential $35 a share, leaving all these other Big Pharma names in the dust... Now, do you see why my #1 bio-tech pick of the year, A5 Laboratories(AFLB), is almost guaranteed to lock in profits of 4694% for early investors? By selecting HERE you'll get the whole story on why A5 Laboratories could be... The Biggest Buyout Target of 2010!! Mark this date on your calender, AFLB could be on it's way to $Billion profits with two ways to win - a high-priced buyout or a profitable licensing agreement - with what could be the single greatest breakthrough in drug technology of our lifetime!! I urge you to read this special report before a buyout or licensing agreement is met, by then it'll be too late. Select here to read on...   Happy Investing, Tim Fields Untapped Wealth IMPORTANT NOTICE AND DISCLAIMER: This featured company sponsored advertising issue of Untapped Wealth does not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by Untapped Wealth or an offer or solicitation to buy or sell any security. A5 Laboratories, (AFLB), the company featured in this issue, appears as paid advertising, paid by Towson Development Ltd. to provide public awareness for AFLB. Towson Development Ltd. has approved and signed off as approved for public dissemination all statements made herein regarding AFLB's history, assets, technologies, current as well as prospective business operations and industry information. Untapped Wealth and Capital Financial Media (CFM) have used outside research and writers using public information to create the advertisement coming from Untapped Wealth about AFLB. Although the information contained in this advertisement is believed to be reliable, Untapped Wealth and CFM makes no warranties as to the accuracy of any of the content herein and accepts no liability for how readers may choose to utilize the content. Readers should perform their own due-diligence, including consulting with a licensed, qualified investment professional or analyst. Further, readers are strongly urged to independently verify all statements made in this advertisement and perform extensive due diligence on this or any other advertised company. Untapped Wealth is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. Many states have established rules requiring the approval of a security by a state security administrator. Check with http://www.nasaa.org or call your state se- curity administrator to determine whether a particular security is licensed for sale in your state. Many companies have information filed with state securities regulators and many will supply investors with additional information on request. CFM has received and managed a total production budget of $1,200,000 for this advertising effort and will retain any amounts over and above the cost of production, copywriting services, mailing and other distribution expenses, as a fee for its services. Untapped Wealth is paid $3,000 as an editorial fee from CFM and also expects to receive new subscriber revenue as a result of this advertising effort. *More information can be received from A5 Laboratories's investor relations firm, or at A5 Laboratories's website www.a5labs.com. Further, specific financial information, filings and disclosures as well as general investor information about publicly traded companies like A5 Laboratories, advice to in- vestors and other investor resources are available at the Securities and Exchange Commission website www.sec.gov and www.nasd.com. Any investment should be made only after con- sulting with a qualified investment advisor and after reviewing the publicly available financial statements of and other information about the company and verifying that the investment is appropriate and suitable. Investing in securities is highly speculative and carries a great deal of risk especially as to new companies with limited operations and no history of earnings. The information contained herein contains forward-looking information within the meaning of section 27a of the Securities Act of 1993, as amended, and section 21e of the Securities Exchange Act of 1934, as amended, including statements regarding expected growth of the featured company. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act, A5 Laboratories notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may af- fect the Company's actual results of operations. Factors that could cause actual results to differ include the size and growth of the market, the Company's ability to fund its capital requirements in the near term and in the long term; pricing pressures, technology issues etc.